Volume 31, Number 6—June 2025
Dispatch
Prevalence of Nitroimidazole-Refractory Giardiasis Acquired in Different World Regions, Sweden, 2008–2020
Karin A. Ydsten
, Joanna Nederby Öhd, Urban Hellgren, and Hilmir Asgeirsson
, Joanna Nederby Öhd, Urban Hellgren, and Hilmir Asgeirsson
Table
Giardiasis by country of acquisition and rate of nitroimidazole-refractory cases, Stockholm, Sweden, 2008–2020
| Origin of infection* | Total no. cases | No. (%) nitroimidazole-refractory cases |
|---|---|---|
| Asia | 1,337 | 73 (5.5) |
| India | 545 | 64 (11.7)† |
| Thailand | 168 | 4 (2.4) |
| Pakistan | 94 | 1 (1.1) |
| Iraq | 71 | 0 |
| Turkey | 65 | 0 |
| Afghanistan | 58 | 0 |
| Syria | 45 | 0 |
| China | 36 | 0 |
| Sri Lanka | 33 | 0 |
| Cambodia | 25 | 0 |
| Indonesia | 25 | 0 |
| Bangladesh | 23 | 2 (8.7) |
| Nepal |
7 |
2 (28.6) |
| Africa | 1,115 | 17‡ (1.5) |
| Tanzania | 136 | 3 (2.2) |
| Somalia | 133 | 1 (0.8) |
| Ethiopia | 105 | 1 (0.9) |
| Kenya | 94 | 0 |
| Eritrea | 93 | 0 |
| Uganda | 65 | 2 (3.1) |
| Egypt | 57 | 0 |
| Gambia | 45 | 0 |
| Sudan | 37 | 0 |
| South Africa | 26 | 1 (3.8) |
| Morocco |
23 |
0 |
| Americas | 349 | 1 (0.3) |
| Colombia | 67 | 1 (1.5) |
| Brazil | 55 | 0 |
| Peru | 36 | 0 |
| Mexico | 28 | 0 |
| United States |
23 |
0 |
| Europe | 1,247 | 11§ (0.9) |
| Sweden | 881 | 5 (0.6) |
| Spain | 107 | 2 (1.9) |
| Greece | 36 | 0 |
| France |
29 |
1 (3.4) |
| Oceania |
5 |
0 |
| Unknown |
232 |
0 |
| Total | 4,285 | 102 (2.4) |
*Countries with >20 giardiasis cases in total are shown, as well as countries with >2 treatment refractory cases. †p<0.0001 for India compared with rest of Asia and for India compared with the rest of the world (by χ2 test). ‡In addition, the following countries had 1 case: Angola, Benin, Central African Republic, Democratic Republic of the Congo, Ghana, Madagascar, Sudan, Chad, and Zimbabwe. §In addition, the following countries had 1 case: Belgium, Italy, and Switzerland.
Page created: April 21, 2025
Page updated: May 27, 2025
Page reviewed: May 27, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.